News & Updates

Treatment with 42-mg lumateperone daily leads to significant improvement in depression symptoms, with no serious safety issues, among patients with major depressive episodes associated with both bipolar I and II disorders, a study has shown.

Mindfulness training (MT) delivered through an app (Unwinding Anxiety) significantly alleviates anxiety, a study has shown. Increases in psychological nonreactivity and reductions in worry mediate the effects of this app, which suggests a specific targeting of reinforcement learning.

In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.

In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.

A recent study indicates that treatment of insomnia with cognitive behavioral therapy for insomnia (CBT-I) has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder compared with sleep education therapy (SET).

In children and adolescents with autism spectrum disorder (ASD), intranasal oxytocin did not improve social interaction or other measures of social function related to ASD, the phase II SOARS-B* trial suggests.

A recent study led by researchers from The University of Hong Kong (HKU) highlights the transient and heterogenous nature of psychotic experiences (PEs), showing that multiple PEs and the hallucination subtype of PEs may be specific indices of poor mental health condition.

A recent study has shown that depression predicts the risk of developing heart failure (HF) with preserved ejection fraction (HFpEF) in late life, and the greater the symptoms, the higher the risk.